Michael Alvarado
Michael Alvarado, M.D. is a Professor of Surgery and member of the breast care and melanoma programs. Just recently, he was appointed Accountable Care Medical Director. Dr. Alvarado received his undergraduate degree from Arizona State University, his master’s degree in chemistry from the University of Arizona and his medical degree from Dartmouth Medical School.
After completing his residency at Dartmouth-Hitchcock Medical Center, he completed his surgical oncology fellowship at the H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida.
Dr. Alvarado plays an integral role in the multidisciplinary breast care team at the Carol Franc Buck Breast Care Center in the UCSF Helen Diller Family Comprehensive Cancer Center. He is also Director of the Breast Surgical Oncology Fellowship Program.

Assoc Professor Yoland Antill works as a Medical Oncologist and as a Cancer Genetics specialist within the public and private sector in Melbourne with over 20 years of experience in each discipline. Her working and research interests are in the management of Breast and Gynaecological cancers together with Hereditary Cancer Syndromes. She is the current chair of ANZGOG’s Uterine Tumour working Group and a member of their Research Advisory Committee. Additionally, she has advisory roles with Breast Cancer Network of Australia, Ovarian Cancer Australia as well as a number of Industry related boards. Yoland is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical and supportive care trials and has published extensively within peer review journals.

Caroline Baker
Caroline is Head of Breast Surgery at St Vincent’s Public Hospital Melbourne, after having serving for 6 years as Director of Breast Services at the Olivia Newton John Cancer and Wellness Centre. She is also Chief Surgeon to St Vincent’s Breast Screen . She gained her FRACS in 1994, then spent 5 years in The UK, subspecialising in the emerging field of breast surgery under the mentorship Mr. Mark Kissin and at The Royal Marsden Hospital in London.
Caroline is a foundation member of BreastSurgANZ, a longterm member of the Australasian Society of Breast Diseases and has been a member of BCT/ANZBCTG since 1998. Caroline regularly teaches students, junior doctors and registrars through The University of Melbourne, lymphoedema practitioners, nurses and volunteers within the Breast Cancer Network of Australia. She has a special interest in neoadjuvant therapy, lymphedema prevention and multidisciplinary care.

Dr. Baron-Hay is a medical oncologist specializing the management of women diagnosed with Breast and Gynaecological cancer at Royal North Shore Hospital, Sydney and Genesis Care, Sydney. Dr Baron-Hay completed her undergraduate training at the University of Western Australia before travelling to London, UK where she worked at the Royal Marsden Hospital in South Kensington establishing her career in Oncology working in the Early Phase trials unit. She completed her physician training at Royal North Shore Hospital and Royal Prince Alfred Hospital. Her early basic research through the Kolling Institute examined the Role of Insulin Like Growth Factors in the pathogenesis of Ovarian Cancer for which was awarded a NHMRC fellowship. Her main interests now include the management of women diagnosed with Breast and Ovarian Cancer and she is the head of the clinical trials unit in these 2 cancer streams at RNSH. She is the PI on both early phase 1/11 and Phase III trials. She was a AI on the “Chemotherapy-Induced Peripheral Neuropathy: assessment strategies, treatments and Risk Factors” 2015 Translational Cancer Grant Program NSW Cancer Institute and is an AI on the “INOVATe-Individualised ovarian. Cancer treatment through integration of genomic pathology into multidisciplinary Care”, initial grant 2015-2019, extended 2020. DR Baron-Hay is a member of the Ovarian Cancer tumour working Group at the ANZGOG. Dr Baron-Hay is a member of the eviQ medical oncology reference committee for both breast and Gynaecological Malignancies. She attends weekly Multidisciplinary meetings in both Breast and Gynaecological malignancies at RNSH, implementing multidisciplinary approached to patient care. She is a supervisor of medical oncology advanced trainees through RNSH and a lecturer in medical oncology for medical students through University of Sydney. She has been involved in both face to face and virtual educational lectures during her appointment at RNSH.

Fran Boyle is a Medical Oncologist at North Sydney’s Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She is a member of the Scientific Advisory committees of BCT and IBCSG and has been involved in all facets of clinical trial research in breast cancer.

Dr Robyn Box MPhty PhD
APA Cancer Care and Lymphoedema Physiotherapist
Robyn has worked in Cancer Care and Lymphoedema for over 35 years in public and private health care settings, completing her PhD in 2000 investigating the effects of Physiotherapy for Breast Cancer Rehabilitation and Early Detection of Lymphoedema introduced initially in 1993. Robyn’s commitment to providing individualized evidence-based best practice culminated in opening a private clinic in 2005, translating her prospective surveillance model into clinical practice. Physiotherapy rehabilitation, exercise prescription, lymphoedema awareness and early detection and management is integral to optimizing health and well-being for patients diagnosed with cancer and/or lymphoedema as part of the “MOVES for Life” programme offered.

Associate Prof Andrew Broadbent BMedSc, MBChB (Otago), MHM (UNSW) FRACP, FAChPM,
Andrew is the Medical Director of the Supportive and Specialist Palliative Services at Gold Coast Health He moved in 2016 from Royal North Shore Hospital and Hammondcare in Northern Sydney.
He has a long-term interest in developing best practice services through redesign and change He has a Master of Health Management at the University of New South Wales that helped give him the theoretical knowledge to do this best as possible along with the practical experience in hospital management at Prince of Wales Hospital in Sydney and that of a Director of Specialist Palliative services for nearly 20 years.

He is the acting chair of the Queensland Health Statewide Palliative Care Network, a member of the Statewide Directors group for Palliative Care in Queensland and a member of the Clinical Council at Gold Coast Health and is an Honorary Adjunct Associate Professor at Bond University

Dr. Julia Camps-Herrero is a breast radiologist and also the Corporate Chief of Breast Health in six Ribera Salud hospitals in Spain (University Hospitals of Torrejon, POVISA, Vinalopó, Denia, and Polusa). From 2006 to 2019 she was appointed Head of the Radiology Department at University Hospital de la Ribera in Alzira (Valencia). Since 1999 she is an active researcher in multimodality breast radiology, with a special interest in MRI. Dr Camps-Herrero is an active speaker in Latin America and Europe, where she has been invited to lecture in more than 370 presentations. She is the author of 23 papers, 7 book chapters and 75 scientific posters and oral presentations. She was appointed Breast Section Editor for EURORAD during 2007-2019, was chairman of the European Congress of Radiology (ECR) 2012 Breast Subcommittee and of the Spanish Senology Congress in 2015, member of the Programme Planning Committee for ECR 2015, 2016 and 2022. Currently, she is the Vice-president of SEDIM (Spanish Breast Imaging Society) and Past-President of the European Society of Breast Imaging (EUSOBI).

Prof Ray Chan (RN, PhD, FACN) is Chair in Cancer Nursing, jointly appointed by Princess Alexandra Hospital, Metro South Health and Queensland University of Technology. Prof Chan’s research program focuses on optimising models of care and health services’ responses to address the needs of people affected by cancer in the survivorship phase. Prof Chan has published 140 peer-reviewed articles. In total, he has attracted >$21.5 million AUD of research funding as Chief Investigator. Prof Chan is an internationally recognised expert in cancer survivorship. He is the current Chair for the Multinational Association for Supportive Care in Cancer (MASCC) Survivorship Group.

Dr Boon H Chua is Professor of Medicine at the University of New South Wales, and Consultant Radiation Oncologist and Director of Cancer and Haematology Services at the Prince of Wales Hospital in Sydney, Australia. With exclusive clinical and academic subspecialisation in breast cancer, she leads an expanding programme of competitive grant-funded, academic oncology research in collaboration with cooperative clinical trials groups worldwide.
She has been actively involved in the Breast International Group (BIG) as Chief Investigator of BIG 3-07/TROG 07.01 DCIS and ANZ 1601/BIG 16-02 EXPERT randomised trials. Dr Chua is voting representative of the Trans-Tasman Radiation Oncology Group (TROG) to the General Assembly, and has been an elected member of the BIG Executive Board since 2017.
Dr Chua holds leadership positions in a diverse range of national and international research and professional organisations. She is current Chair of the TROG Breast Group, Scientific Advisory Committee Executive of Breast Cancer Trials (BCT) Australia and New Zealand, and Scientific Committee member of international congresses.

Dr Steven David is a radiation oncologist who graduated from the University of Western Australia before completing his specialist training at the Peter MacCallum Cancer Centre in Melbourne. Subsequently, he took up a position as a sub-specialist in breast and lung cancer at the Peter MacCallum Moorabbin campus (Monash Cancer Centre). Steven has been the lead investigator in a number of local clinical trials and has been involved in recruitment to a number of international trials. His current areas of research include development and implementation of a Deep Inspiration Breath Hold Technique to reduce radiation to the heart for patients with left sided breast cancer and the use of high dose precision radiation (SABR) for the treatment of patients with metastatic disease.

Dr. Richard De Boer completed his basic medical and oncology training at the Royal Melbourne Hospital and then in 1997 undertook a 3-year breast and lung cancer clinical research fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. His primary areas of clinical interest are in breast and lung cancer, with breast cancer interests focusing on endocrine therapy and mechanisms of resistance, treatment-induced bone loss and bone metastases, and biological predictors of response/survival. He is actively involved in clinical research, and is a member of the Australian New Zealand Breast Cancer Trials Group, and head of the Breast Trials group of Cancer Trials Australia. He has authored or co-authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Rebecca Dent is Senior Consultant in the Department of Medical Oncology, National Cancer Center Singapore and is Chief of the Breast Medical Oncology Service.
She is also an Associate Professor at Duke-National University Singapore Medical School. Dr Dent received her medical degree in 2000 from McMaster University in Hamilton, Canada, and obtained her Master of Science degree in clinical epidemiology and biostatistics from the University of Toronto, Canada. She obtained her internal medicine and medical oncology training at the University of Toronto, Canada.
Dr Dent’s primary research interest is in the field of breast cancer, focusing on locally advanced breast cancer and triple-negative breast cancers. She is principal investigator for several clinical trials for the treatment of preoperative and advanced breast cancer. She serves on a number of scientific committees at ASCO, ESMO and ESMO Asia.

Elisabeth Elder is a specialist breast surgeon at the Westmead Breast Cancer Institute and Clinical Associate Professor at the University of Sydney, with a special interest in oncoplastic and reconstructive surgery. She is involved in numerous research projects and clinical trials within the Westmead Breast Cancer Research Collaborative. She graduated from the Karolinska Institute in Sweden in 1992, where she also completed her general surgery training and a PhD in tumour biology in 2002. She is the President of ASBD and previous chair of the oncoplastic committee of Breast Surgeon in Australia and New Zealand and council member of Breast Surgeons International. She regularly participates in breast cancer education for medical professionals, students as well as patient groups and the broader community.

Prudence Francis commenced Medical Oncology training in Australia and subsequently completed training in the USA. She spent 4 years at Memorial Sloan-Kettering Cancer Center in New York. In 1994 she was appointed as a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne. Since 2003 she has been the Clinical Lead for Breast Medical Oncology at Peter MacCallum. She is Chair of the Scientific Advisory Committee of the Australia New Zealand Breast Cancer Trials Group (ANZ BCTG). She is a member of the Scientific Committee of the International Breast Cancer Study Group (IBCSG). She is a panel member on the Advanced Breast Cancer (ABC) International Consensus Panel and the St Gallen International Consensus Panel for Primary Therapy of Early Breast Cancer. As a clinician researcher she has focused much of her research on randomized breast cancer trials.

Dr. Jemma Gilchrist is a senior clinical psychologist who has a special interest in the emotional care of individuals with cancer and their families. Since 1999, Jemma has worked in cancer centres in the public and private sector. She is actively involved in research to develop new ways of treating common fears and concerns as well as optimising communication between patients and health care professionals. Jemma is currently working clinically at Crown Princess Mary Cancer Centre and her private practice, “Mind My Health”, in Sydney.

Jenny Gilchrist is a Nurse Practitioner in Breast Oncology at Macquarie University Hospital, one of only four breast cancer specialist nurse practitioners in Australia. She also works for the McGrath Foundation as the Chief Clinical Lead for the Metastatic McGrath Breast Cancer nurses.

Jenny has twenty years nursing experience in oncology and palliative care, in both adults and children, and holds an honorary position as Senior Lecturer at Macquarie University. She a member on the board of directors of the Australasian Society for Breast Diseases and is a sub-investigator on several phase 2 and 3 breast cancer clinical trials at Macquarie University.

Her clinical interests and passions include breast cancer, supportive care and the prevention of burnout in healthcare professionals. Jenny also has a strong interest in clinical research, particularly that which aims to improve patient symptoms, care and quality of life.

Dr Phillip Good is a Palliative Medicine Specialist working at Mater Health Services and St Vincent’s Private Hospital, Brisbane. He also has an appointment as a Clinical Professor at the University of Queensland, and Associate Professor at University of Technology Sydney. He tries to combine clinical practice in palliative care with research aimed at improving patient outcomes.

Martha Hickey is Professor of Obstetrics and Gynaecology at the University of Melbourne and an NHMRC Practitioner Fellow. She initially trained and worked as a Clinical Psychologist, and then studied medicine at Bristol University, She was awarded Doctorate in Reproductive Health from Bristol University and moved to Australia from Imperial College London in 2001. She is a member of the World Health Organisation Human Reproduction Program Research Panel and Senior Editor for the Cochrane Collaboration. Professor Hickey has clinical and research interests in menopause, and in particular the management of menopause after cancer.

Alice Ho
My clinical practice is devoted solely to treatment of breast cancer patients. My research focuses on improving clinical outcomes in breast cancer patients and reducing toxicities related to radiation treatment for breast cancer. I am engaged in 3 lines of research: 1) Developing clinical trials that examine rationale combinations of radiation with DNA repair-based therapy or immunotherapy in patients with refractory/recurrent triple negative breast cancer (TNBC) 2) Applying innovative medical physics techniques (i.e. intensity modulated radiation therapy; IMRT) in order to minimize radiation toxicities for breast cancer patients with implant reconstructions 3) Identifying novel imaging modalities that can serve as early surrogates of cardiotoxicities following radiation for breast cancer.

Assoc Prof Paul A James is a Clinical Geneticist from Melbourne. He is the director of the Parkville Familial Cancer Centre (Royal Melbourne Hospital and Peter MacCallum Cancer Centre) and Head of Clinical Genetics in the Department of Genomic Medicine (RMH). He leads a program of clinical research including discovery and translational projects emphasising familial cancer and the genetics of inherited cardiac disorders, and is a group leader in Familial Cancer research at Peter MacCallum.

Prof. Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at the Royal Marsden. He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997. He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and is chief investigator of several phase II / III trials of novel therapeutic approaches in advanced disease, including new endocrine therapies and targeted signal transduction inhibitors. He has published over 230 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of several scientific committees and advisory boards, a Faculty Member at the American Society for Clinical Oncology, the Deputy-Editor of the international journal ‘Breast Cancer Research’, and a former Trustee of the UK charity ‘Breast Cancer Campaign’ having also been Chairman of their Scientific Advisory Board.

Dr. David Kirchhoffer is Director of the Queensland Bioethics Centre at Australian Catholic University. He conducts research, teaching and consultancy in bioethical issues. In addition to numerous scholarly articles and book chapters, he is the author of Human Dignity in Contemporary Ethics (Teneo Press, 2013) and co-editor with Bernadette Richards of Beyond Autonomy: Limits and Alternatives to Informed Consent in Human Research Ethics (Cambridge UP, 2019).

Dr Louise Koelmeyer is the Director of the Australian Lymphoedema Education, Research and Treatment (ALERT) program at Macquarie University and is involved in strategically managing and developing the education, research and treatment arms of the innovative and internationally recognised “Centre of Excellence” multidisciplinary program. Louise is a lymphoedema therapist (Occupational therapist), educator and researcher with over 30 years of experience in both public and private settings specialising in breast cancer rehabilitation and lymphoedema management. Her area of interest is on the prospective surveillance and early intervention model of care for the early detection and management of lymphoedema as well as innovative advances in conservative and surgical management.

Sanjeev Kumar is a Medical Oncologist and Clinician Scientist who grew up in country NSW, before completing undergraduate medical studies at the University of New South Wales in 2006. He trained as a Medical Oncologist at Royal Prince Alfred Hospital, the Chris O’Brien Lifehouse and in the United Kingdom.
Sanjeev moved to Cambridge (UK) in 2015 to undertake a Drug Development Fellowship. He was then awarded a University of Cambridge scholarship in 2016 to complete a cancer molecular biology PhD at the Cancer Research UK Cambridge Institute, with a focus on Oestrogen receptor-positive breast cancer. Simultaneously, he ran a UK-wide clinical trial for patients with ER-positive breast cancer. Sanjeev has now returned to Australia where he continues his clinical and academic focus on breast cancer with positions at the Chris O’Brien Lifehouse, The Kinghorn Cancer Centre and the Garvan Institute of Medical Research. He has a keen interest in the education of trainees, public engagement and clinical trials.

Sunil Lakhani is a clinical diagnostic and molecular pathologist. He is the Executive Director of Research and Senior Staff Specialist at Pathology Queensland and Head of the Breast Group, University of Queensland Centre for Clinical Research (UQCCR), Brisbane, Australia. His current interests include lobular carcinoma and its variants, triple negative and metaplastic breast cancer and the mechanisms and therapeutic development of brain metastases.
He was Editor of the WHO 4th Ed Tumours of the Breast (2012) and is Editor and Standing member of Board of WHO 5th Ed Tumours of the Breast (2019). He is an elected Board member of Breast Cancer Trials.
He is the recipient of the Distinguished Pathologist Medal, Australasian Division of the International Academy of Pathology and The Distinguished Fellow Award, The Royal College of Pathologists of Australasia. In 2017, he was elected Fellow of the Australian Academy of Health and Medical Sciences.

Brian Le is the Director of Palliative Care at the Victorian Comprehensive Cancer Centre, including the Peter MacCallum Cancer Centre and The Royal Melbourne Hospital.
He is a Palliative Medicine Physician and Medical Oncologist, and is an Associate Professor of the University of Melbourne.
Brian has published over 85 peer reviewed scientific papers and book chapters, is involved in palliative care research including clinical trials and health services research.
Brian is a past Chair of the Palliative Medicine Training Committee of the Royal Australasian College of Physicians, responsible for training of all palliative medicine specialists in Australia and New Zealand, and past Chair of Palliative Care Victoria.

Dr Ying Li (BSc (Med) MBBS MBA FRANZCOG CREI) is a subspecialist in reproductive endocrinology & infertility and an advanced endoscopic reproductive surgeon. He is a visiting medical officer at Sydney’s Royal Prince Alfred Hospital and at Genea Fertility. He is a fellow of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists and is one of a few certified subspecialists in reproductive endocrinology & infertility (CREI). He has an interest in female & male fertility preservation and is also a member of Australia’s first approved uterus transplant unit.

Assoc Prof Rhea Liang (MBChB, BA(Ed), MSurgEd, FRACS, FACS, FFSTEd) is a general and breast surgeon on the Gold Coast, surgical educationalist, Surgical Discipline Lead at Bond University and immediate past Chair of the RACS (Royal Australasian College of Surgeons) Operating With Respect Education Committee. She grew up and completed her training in New Zealand, and initially arrived on the Gold Coast for a short stint but soon found herself helping to set up the Gold Coast HHS Breast Service and is still there 14 years later. She has a passion for breast cancer care that extends well beyond the provision of medical treatments and continues ‘traditional’ quantitative breast cancer research as well as qualitative research about breast cancer decision-making, treatment experiences and survivorship. She tweets at @LiangRhea.

Prof Elgene Lim is a medical oncologist at The Kinghorn Cancer Centre, St Vincent’s Hospital, and leads the Connie Johnson Breast Cancer Research Group at the Garvan Institute of Medical Research. He obtained his training at the University of Melbourne, Walter& Eliza Hall of Medical Research, and Dana-Farber Cancer Institute. He is the inaugural National Breast Cancer Foundation Endowed Chair and a clinical academic at the UNSW medical school. His research team performs clinically focused laboratory research, utilizing patient-derived breast tumour xenografts for the evaluation of novel therapies. A major focus of his group is on overcoming resistance to currently used endocrine therapies. His research is funded through the National Breast Cancer Foundation, Cancer Australia, Cancer Council of NSW, National Health and Medical Research Council, Love Your Sister, the Garvan, Balnaves, Curran and St Vincent’s Clinic Foundation.

Jocelyn Lippey is a breast surgeon from Melbourne, Victoria working at St. Vincent’s and BreastScreen as well as St. Vincent’s East Melbourne privately.

She was a current recipient of an NBCF practitioners grant to develop a risk communication tool for risk-stratified Breast screening which is also her PhD thesis due to finish in 2024. She also co-ordinates a unit of study for University of Sydney’s Masters of Breast Surgery.

Her research interests include DCIS, risk communication, tailored breast screening and patient reported outcome measures..

Sheau Wen Lok is a breast oncologist at Peter MacCallum Cancer Centre and a Cancer Genetics specialist at the Parkville and Austin Familial Cancer Centres. She obtained her medical degree from the University of Melbourne in 2004 and completed her medical oncology training in Melbourne. She subsequently worked as a clinical research fellow at the Centre for Translational Breast Cancer Research at Walter and Eliza Hall Institute, developing translational research programs and early phase clinical trials to maximise delivery of new breast cancer therapies arising from home-grown laboratory discoveries. Her current research interest is focused on harnessing real world evidence through multi-centre breast cancer registries to inform clinical practice. She is also the Australian co-chair of the ‘BRCA-P’ study, an international breast cancer prevention trial for women who carry a BRCA1 gene mutation.

Douglas Macmillan is clinical lead and oncoplastic surgeon at the Nottingham Breast Institute, UK. He is co-director of ORBS, the international conference on oncoplastic and reconstructive breast surgery (www.orbsmeetings.com) and has published over 200 articles and book chapters. He has given over 300 invited presentations at international meetings and performed many live surgery demonstrations and has a particular interest in techniques of breast conserving surgery, breast reconstructive surgery and cosmetic breast surgery.

A/Prof Cindy Mak is a breast surgeon. She is the Director of Breast Services at Chris O’Brien Lifehouse and Royal Prince Alfred Hospital. She also practices at the Mater Hospital in North Sydney. She completed her surgical training in Sydney and at the Edinburgh Breast Unit. Cindy is chair of the oncoplastic subcommittee of BreastSurgANZ, and has been involved in TGA working groups and MSAC applications for MBS item numbers. She is a clinical Associate Professor at Sydney University and is involved in research through the Institute of Academic Surgery at RPAH.

Prof. Bruce Mann is Professor of Surgery at the University of Melbourne and Director of The Breast Service at the Royal Melbourne and Royal Women’s Hospital in Melbourne. He is on the council of Breast SurgANZ, the Scientific Advisory Committee of the ANZ Breast Cancer Trials Group and is past president of the Clinical Oncology Society of Australia. He has been involved in many clinical trials and much clinical and translational research regarding breast cancer, with his main research interest being tailoring treatment to the disease and the patient.

Ritse Mann is a breast and interventional radiologist, working at the Radboud University Medical Centre in Nijmegen, as well as the Netherlands Cancer Institute in Amsterdam. He leads clinical radiological breast research at both hospitals. He is currently chair of the scientific committee of the European Society of breast imaging (EUSOBI), and section editor Women’s Imaging for the European Journal of Radiology. He is course director of the annual Nijmegen Advanced Breast Imaging Course, as well as the Cairo based course DETECT, has been member of the program planning committee for breast for ECR from 2012-2015 and is currently member of the scientific program planning committee for breast of the RSNA. He leads and participates in many clinical trials on the clinical value of new and existing imaging modalities for detection and classification of breast lesions, with a particular focus on breast MRI.

Dr Helen Mar Fan is a dual trained medical oncologist and cancer geneticist who works in the cancer service at Genetic Health Queensland and is currently seconded to Cancer Services at the Royal Brisbane and Women’s Hospital. She has an interest in the education of non-genetic health professionals in the ordering and interpreting of genetic tests and in the development of evidence-based guidelines for genetic testing and risk management for individuals with familial cancer predisposition syndromes.

Nicole McCarthy
Associate Professor Nicole McCarthy MBBS (Hons), MHSc, FRACP is a Consultant Medical Oncologist at Icon Cancer Care at the Wesley Medical Centre and Wesley Hospital in Brisbane and her academic appointment is with the School of Medicine, University of Queensland . She completed a 3 year Medical oncology fellowship at the National Cancer Institute, Bethesda MD and a Masters in Health Sciences in Clinical Trial Design through Duke University. She is an academic clinician and her clinical practice and translational research focuses on the multifaceted aspects of breast cancer care and management. She led the Breast Cancer Clinical trials unit at the Royal Brisbane and Women’s Hospital for over 10 years and now provides leadership for the breast cancer clinical trials component of ICON Research Foundation Clinical Trials Unit, the largest national private oncology provider. A/Prof McCarthy is considered an opinion leader in breast cancer management at a local and national level and her own investigator-initiated clinical trials have been incorporating new agents into neoadjuvant breast cancer treatment. A/Prof McCarthy has been the Chair of the Systemic Therapy Subcommittee of the ANZ Breast Cancer Trials Group Scientific Advisory Committee (SAC) since 2007 and a member of the SAC since 2004. She has been the Australian Principal Investigator on several international clinical trials. A/Prof McCarthy has been a member of a number of national breast cancer guideline panels and has played a close role with breast cancer consumer advocacy groups.

Sam Mills is the Senior Policy Officer at national consumer breast cancer organisation, Breast Cancer Network Australia (BCNA).
He assists in leading BCNA’s policy and advocacy priorities by representing those affected by breast cancer at a state/territory and national level. This work involves the leveraging of consumer insights to advocate for system and policy changes to ensure all those affected by breast cancer receive the best possible care.
Sam has an academic background in public health policy and has worked at various levels of government as well as NGOs in both Australia and New Zealand.

Associate Professor Carolyn Nickson is an epidemiologist specialising in the evaluation of breast cancer screening, diagnosis and treatment. She heads the Breast Cancer Policy and Evaluation stream at The Daffodil Centre (a new joint venture between Cancer Council NSW and the University of Sydney), and the ABACUS research group at the University of Melbourne. Her projects include leading the Australian Government funded ‘Breast ROSA’ project on behalf of Cancer Council Australia, which is exploring options for more risk-based approaches to breast cancer screening in the Australian setting through a combination of epidemiological studies, population modelling and policy and implementation activities.

Dr Jenny O’Sullivan
Jenny O’Sullivan graduated in Medicine at Sydney University in 1988. After spending several years in General Practice she commenced training as a Breast Physician at the Sydney Breast Clinic in 1996. Jenny achieved Fellowship of the Australasian Society of Breast Physicians in 2005. She moved to Auckland in 2005 where she worked at St Marks Breast Clinic, then returned to Sydney in 2008 to take up roles at Breastscreen NSW and Royal North Shore Hospital. She also works in private practice at Mater Clinic Sydney.
Jenny has extensive experience in the diagnosis and management of breast cancer as well as benign breast disorders and breast cancer risk management.
Qualifications
MB, BS
Fellow of the Australasian Society of Breast Physicians
Master of Psychological Medicine (UNSW, 2000)
Current Appointments
Staff Specialist, Area Cancer Services, Royal North Shore Hospital
(Northern Sydney Central Coast LHD) since 2010
VMO BreastScreen NSW, Sydney LHD and Sydney South West LHD since 2008
VMO Mater Clinic, North Sydney since 2015

Ann Partridge, MD, MPH is a Professor of Medicine at Harvard Medical School, and Vice Chair of Medical Oncology at Dana-Farber Cancer Institute, where she also serves as Director of the Adult Survivorship Program and leads the Program for Young Women with Breast Cancer. As a medical oncologist and clinical researcher, she has sought to improve the care and outcomes of patients with cancer by conducting research, and by developing innovative clinical programming. Dr. Partridge serves in leadership roles nationally and internationally including as co-chair of the Breast Committee of the Alliance for Clinical Trials in Oncology and co-chair of the biennial ESMO-ESO sponsored Breast Cancer in Young Women Conference. She also served as Chair of the Center for Disease Control and Prevention (CDC) Advisory Committee on Breast Cancer in Young Women from 2010-17. She has received prior awards and grants including a Champions of Change award from the White House, an ASCO Improving Cancer Care Grant, the CDC Carol Friedman Award, the American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer, and the Ellen L. Stovall Award in Cancer Survivorship from ASCO, and the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School.
After graduating from Georgetown University, Dr. Partridge received her medical degree from Cornell University Medical College, pursued an internal medicine residency at the Hospital for the University of Pennsylvania, and completed Medical Oncology and Hematology fellowship at Dana-Farber/Partners CancerCare. She earned a Master of Public Health degree at the Harvard School of Public Health.

Kerry Patford brings more than 30 years’ of nursing experience to her role as the Chief Clinical Leader for the McGrath Foundation where she provides support and advice and assists in the professional development of McGrath Breast Care Nurses right across Australia.

Kerry leads a team of Clinical Leaders to deliver key projects around breast care nursing practice, professional development and support to over 160 McGrath Breast Care Nurses. She maintains her clinical currency practising as a McGrath Breast Care Nurse in regional Victoria and provides leadership and expertise to other cancer care organisations, universities and governments, consulting on a range of projects to improve care and treatment for patients and their families.

Associate Professor Nirmala Pathmanathan, BSc (Med), MB, BS, FRCPA, MIACAssociate Professor Nirmala Pathmanathan is an anatomical pathologist with expertise in breast diseases. She is the Director of the Westmead Breast Cancer Institute in Sydney, which is a comprehensive multidisciplinary breast cancer program covering Western Sydney. She is also the Director of the BreastScreen Program for Sydney West and the Designated/Lead Pathologist for this program. She is a Clinical Associate Professor with the University of Sydney and Conjoint Associate Professor with the University of Western Sydney. A/Prof Pathmanathan is currently a specialist breast pathologist at Douglass Hanly Moir Pathology (part time).
A/Professor Pathmanathan is the recipient and chief or principal investigator on a number of grant-funded projects and is a past executive committee member of the Australian Breast Cancer Tumour Bank. She is a Member of NBOCC Sentinel Node Biopsy Subgroup and was involved in the development of recommendations for use of Sentinel Node Biopsy in Breast Cancer. Recently, A/Professor Pathmanathan has been a steering committee member in the development and presentation of breast cancer workshops, aimed at improving the quality of breast cancer pathology and HER2 testing in several countries across the Asia Pacific Region. She sits on the Executive Committee for the Australasian Society for Breast Diseases and is a National Clinical Advisory Board Member for BreastScreen Australia. Her primary research interests are in HER2 testing, prognostic markers in ER positive breast cancer and borderline/atypical lesions of the breast.

Dr. Antonia Pearson is a medical oncologist with a focus on breast, gynaecological and lung cancers. She completed her training in Sydney and is now practising at Northern Beaches Hospital and Genesis. She is currently completing her PhD on genitourinary symptoms in breast cancer and as a part of this has two clinical trials, for the treatment of these symptoms, currently recruiting patients across Sydney.

Dr. Heidi Peverill is a Oncoplastic Breast, Melanoma and General Surgeon in Brisbane.
She has completed a Master of Advanced Breast Surgery and has been a full member of BreastSurgANZ since 2013.
As a member of both the RACS Younger Fellows committee and Women in Surgery section, Dr Peverill supports and advocates for progression opportunities for both young surgeons and women in medicine.
Dr Peverill also serves as a national committee member and senior instructor for the Care of the Critically Ill Surgical Patient curriculum.
She supports these programs in tandem with her own research in breast cancer prevention in young women.
Dr Peverill is currently publicly employed at the Princess Alexandra Hospital and privately she can be seen at ORBE Surgeons at the Mater Private Hospital.

Kirsten Pilatti
Chief Executive Officer

Kirsten Pilatti was appointed CEO in March 2018.
She has an exceptional understanding of the cancer sector having spent over a decade at BCNA.
Highly regarded for her passion and focus on Australian women and men who have been affected by breast cancer, she is committed to giving everyone a voice and reducing the disparity of care across the country.
Her deep connection to our 150,000 members was cemented after spending 18 months travelling around Australia interviewing more than 3,500 women and men about their experience of breast cancer treatment and services to find out where the gaps in service delivery are occurring. The findings were outlined in the State of the Nation report, which was delivered to Federal Parliament in June 2018.
She is also proud of the work she has done to turn the spotlight on important issues such as access to breast reconstruction, the out of pocket costs experienced by breast cancer patients, driving changes to the Australian healthcare system including access to drugs through the PBS such as the CDK inhibitors for Australians with metastatic breast cancer.
Kirsten understands the power of sharing the experiences of those diagnosed and living with breast cancer. She will continue to be their advocate until all Australians receive the very best care, treatment, and support.
Born and raised in Western Australia, Kirsten lives in Melbourne with her partner and two sons.

Dr Bridget Pratt is an ethics researcher and the Mater Lecturer/Senior Lecturer in Healthcare Ethics at Queensland Bioethics Centre at Australian Catholic University. She is a KNAW Visiting Professor at the Julius Centre for Global Health at Utrecht University in the Netherlands.
Bridget’s research interests include the ethics of global health research, health systems, and urban planning, with a focus on equity and social justice. She has developed ethical guidance on the following topics: research priority-setting, research governance, community engagement, ancillary care, capacity development, post-study benefits, and data sharing.

Nick Repin is a diagnostic and interventional radiologist based near Lismore in regional NSW, Australia. His subspecialty interests include breast imaging in the context of population screening, and the roles of interventional radiology in breast disease. He is active both in public hospital and private practice, has been reading and assessing in NSW BreastScreen for 20 years, and is Designated Radiologist both for BreastScreen NSW North Coast and BreastScreen Tasmania.

Dr. Alistair Ring is a Consultant Medical Oncologist at The Royal Marsden. He undertook his pre-clinical training at the University of Cambridge and clinical training at the University of Oxford, qualifying in 1997. His oncology training was based at The Royal Marsden, St George’s and Guy’s Hospitals, London. He gained his MD research degree in 2005 from the Institute of Cancer Research (ICR) at the University of London.
In 2008 he was appointed as Senior Lecturer in Oncology at Brighton and Sussex Medical School, where he held various roles including Director of the Brighton NIHR Clinical Research Facility. In 2014 he was appointed Consultant Medical Oncologist at The Royal Marsden.
He has specialist interests in the management of metastatic and early breast cancer and the management of cancer in older patients. He has a major interest in research, and is UK lead for a number of research studies examining the roles of aspirin and modern targeted drugs in the management of breast cancer. He is Chair of the Committee for Clinical Research at The Royal Marsden and the ICR. Dr Ring has published widely in peer-reviewed journals and in 2015, edited the textbook Problem Solving in Older Cancer Patients and in 2017 Breast Cancer Survivorship.
In 2018 Dr Ring was appointed Honorary Reader in Breast Cancer Clinical Trials, at the Institute of Cancer Research.

Mark E. Robson, MD
Chief, Breast Medicine Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
Dr. Robson graduated from the University of Virginia School of Medicine in Charlottesville, Virginia, and did his internal medicine residency and hematology-oncology fellowship training at Walter Reed Army Medical Center in Washington DC. He is currently Chief of the Breast Medicine Service in the Department of Medicine at Memorial Hospital in New York, Attending Physician on Breast Medicine and Clinical Genetics Services, and a Member of the Memorial Sloan Kettering Cancer Center. His clinical research has concentrated on the optimal application of germline information to the management of cancer patients, particularly those with breast cancer. He has been a lead investigator for a number of trials of PARP inhibitors in patients with BRCA mutation – associated breast cancer. In addition to studying PARP inhibition as a therapeutic strategy, he is currently developing new models for the acquisition of germline information, including “mainstreaming” through test ordering by primary oncology providers and broad genomic screening in the context of somatic mutational profiling. He is also investigating the use of polygenic risk scores in facilitating decision-making among women with or without an inherited predisposition. He is an associate editor for the Journal of the National Cancer Institute. He is a Fellow of the American Society of Clinical Oncology, past Chair of the Ethics Committee of that organization and has served several terms on the ASCO Cancer Prevention Committee and its Cancer Genetics subcommittee.

Dr Allison Rose MB. BS, M. MED, FRANZCR
Director, Northwestern BreastScreen
Head, The Royal Melbourne & The Women’s Hospital Breast Imaging Service Consultant Radiologist, The Royal Melbourne Hospital Associate, University of Melbourne Radiology Department.Dr Allison Rose worked at the Victorian Pilot Program for the Early Detection of Breast Cancer from 1989 under the auspice of The Royal Melbourne Hospital and became Director in 1999. In 2009 she became Head of Breast Imaging for the combined Royal Melbourne & The Women’s Hospital Breast Service & in this role she has led the team to deliver fully integrated comprehensive breast imaging across diagnostic and screening sites. She was instrumental in establishing Breast MRI & MRI guided biopsy for the service and more recently developed protocols for contrast enhanced digital mammography. Her current interests are focussed on risk based tailored breast screening and appropriate staging of diagnosed breast cancer- BreastStage.

Professor Christobel Saunders AO, is internationally recognised as one of Australia’s most prominent research-orientated cancer surgeons. She has substantially contributed to breast cancer research including clinical trials of new treatments, psychosocial, translational and health services research and is active in several areas of surgical oncology cancer research, with a particular emphasis on breast cancer. In recognition of her sustained career excellence and innovation, Christobel has been publicly acknowledged through numerous awards and honours the most recent being the AO (Order of Australia) (2018), Uccio Querci della Rovere Award (2018), International Women’s Day WA Women’s Hall of Fame Inductee (2018) and WA Scientist of the Year (2017). She has performed research for >30 years evaluating the efficacy and utility of therapy for early breast cancer. In the past five years, Christobel has published over 100 peer-reviewed journal articles (two in The Lancet), six letters to the editor/editorials, two research reports, two book chapters and one book. She sits on the boards of a number of cancer organisations including the ANZ Breast Cancer Trials Group. Christobel is closely involved in strategic planning and management of cancer services in Western Australia as author of the WA Health Cancer Services Framework and as first A/Director, WA Cancer and Palliative Care Network, past President of the Cancer Council WA, past President of the Breast Surgical Society of ANZ, and nationally as past Advisory Council member of organisations such as Cancer Australia. She is the Inaugural Chair of the state Health Service Provider, PathWest Laboratory Medicine..

Kerry Shanahan (RN; GrDHealthSci) works as Breast Cancer Clinical Nurse Consultant at the Royal Melbourne Hospital since 1998, providing education, support and co-ordination of care for women/men experiencing early and advanced breast cancer, across the continuum of care. Particular area of interest is survivorship and shared follow-up care in early breast cancer, with involvement in many working groups and provision of mentorship.

Dr Catherine Shannon is Senior Medical Oncologist at the Mater Cancer Care Centre, Director of Medical Oncology Clinical trials unit, a member of Mater Research’s Clinical Research group and Senior Lecturer at the University of Queensland, Brisbane, Australia. She is the Principal or Co-investigator on a number of Phase I, II and III clinical trials in breast and gynaecological cancer. She is currently on the Executive Committee of the Australian Society of Breast Disease and member of the Breast cancer advisory panel for Cancer Australia.
Dr Shannon has a special interest in the management of breast cancer in young women and pregnant women and has published in this field. Dr Shannon recently started a private practice at the Mater Cancer Care Centre in South Brisbane. Her research publications include the molecular genetics of synchronous gynaecological tumours and neoadjuvant therapies for breast cancer. Dr Shannon acted as Chair at the committee for writing endocrine therapy guidelines for the management of advanced breast cancer.

Anna Singleton is an early-career researcher (MSc Experimental Psych; BSc Hons I Psych), a PhD candidate and research associate at the University of Sydney with >247K in research prizes and awards, including $52K as CIA. Her research focuses on co-designing (cancer survivors, health professionals) scalable, low-cost digital health strategies (eg. text messages, mobile apps) to support health of breast cancer survivors, with the ultimate goal of lowering risks factors for cardiovascular disease and cancer recurrence. In the last 3 years, Anna Singleton hase recruited >1000 breast cancer survivors to her digital health studies (clinical trial, nation-wide observational study), which patients found useful (91%), easy-to-understand (100%) and motivating for improving health (76%). Anna has also 16 published peer-reviewed manuscripts (3 first-author, 1 last-author), with many in high-ranking journals such as BMJ Heart, BMC Cancer, and Obesity reviews.

Andrea Smith is a consumer and researcher, having been diagnosed with metastatic breast cancer in 2016. She is a Daffodil Fellow at The Daffodil Centre, University of Sydney, a joint venture with Cancer Council NSW. Her work focuses on the implementation of evidence into practice, specifically in breast cancer and melanoma, using qualitative and mixed methods. In addition to being a consumer representative for the Breast Cancer Network Australia (BCNA) Seat-At-The-Table program she chairs the BCNA Metastatic Breast Cancer Advisory Group and is a member of the Board Directors for the ABC Global Alliance.

Dr. Cameron Snell is head of Anatomical Pathology at Peter Mac in Melbourne, Australia. He has an active interest in quality in immunohistochemistry and sits on the Board of Professional Practice and Quality for the Royal College of Pathologists of Australasia and is a current NATA (National Association of Testing Authorities, Australia) assessor. Dr. Snell has active research interests including novel diagnostics in the personalisation of cancer therapy and algorithm-assisted quantification of biomarkers. Dr. Snell is a past Nuffield Fellow and has completed a research DPhil (clinical laboratory sciences) from the University of Oxford.

Jodi Steel was diagnosed with breast cancer in 2016. She is a member of BCNA’s Consumer Representative (CR) Program, Seat at the Table. As a BCNA CR, she is currently providing consumer input on a project developing an Arabic breast reconstruction decision aid.

In 2019, prior to becoming a BCNA CR, she was patient advisor on a University of Wollongong project to develop an online resource for preparation and initial recovery from breast reconstruction. Prior to her diagnosis, she worked for over 20 years in the translation and commercialisation of basic and applied Information and Communication Technology (ICT) research.

Professor Alastair Thompson trained and practiced as a clinician-scientist focused on multidisciplinary patient care alongside translational “bench to bedside” studies and innovative clinical trials in cancer. He initiated and led a successful breast cancer laboratory program and provided leadership for a cancer center in Dundee, United Kingdom (UK). He chaired the UK national breast cancer trials portfolio of 120 studies led the national breast cancer tissue bank and engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, the United States and Australia. Since moving to the US in 2014, he has focused on improving treatment for breast cancer patients with innovative surgical techniques and clinical trials.
Thompson is an active member of SSO, ASBrS, ASCO and AACR. With successful peer reviewed funding from US government and international charitable sources spanning laboratory to clinical studies, successful supervision of 24 postgraduate students to date and over 400 publications in the highest impact factor clinical and scientific journals. His key mission remains improving care for those with cancer.

Dr Elysia Thornton-Benko is a Specialist General Practitioner/Family Physician who cares for all age groups, genders and medical conditions including preventative health and wellness. She is also a Research Fellow with the University of New South Wales, Faculty of Medicine, Behavioural Sciences Unit, Kids Cancer Centre, Sydney.
Elysia has a special interest and expertise in Cancer Survivorship. Prior to entering General Practice, Elysia worked for various hospital oncology units including 2 years in Radiation Oncology specialty training and 6 months as a community palliative care registrar. Elysia currently works in a consulting, research and advisory capacity on a variety of national and local cancer and cancer survivorship projects and executive committees. Elysia feels strongly about the need for integration of primary care throughout the cancer trajectory by the establishment of more standardised frameworks and pathways. She is an advocate for cohesive collaborative care between all involved health professionals. This will ultimately lead to delivering optimal care to cancer patients, survivors and their families, with enhanced support and improved quality of life.

Dr Charlotte Tottman (PhD, Clin Psych) works as a Clinical Psycho Oncologist. She consults privately, providing psychological treatment for cancer-related distress. Charlotte works with cancer patients and their family members and carers, at all stages of their cancer experience. Charlotte works closely with Breast Cancer Network Australia (BCNA) and is a member of the BCNA Strategic Advisory Group. She is an Editor for the Cancer Council of Australia, and has strong links with the McGrath Foundation, CanTeen, and Ovarian Cancer Australia.

Dean Trotter is the head of the Plastic & Reconstructive Surgery unit at the Women’s Hospital, Melbourne and clinical lead of the breast reconstruction service at the Royal Melbourne Hospital. He completed a fellowship in microsurgery at the St Andrew’s Centre in the UK in 2009-10 and has performed over 850 breast reconstructions in both public and private practice since his return to Melbourne in 2011. Dean has a sub-speciality interest in breast reconstruction following risk-reduction mastectomy.

Jane Turner has worked for 25 years as a consultation-liaison psychiatrist in oncology. She has extensive experience in the development and implementation of clinical practice guidelines. She was an Investigator on the successful Australian multi-site trial of a manual-based intervention for fear of cancer recurrence.
She is President-Elect of the International Psycho-Oncology Society (IPOS) and chairs the IPOS-WHO committee which aims to promote psychosocial care in low and middle-income countries. In this capacity she is engaged in initiatives to embed psychosocial care in clinical practice and national cancer control plans.

Professor Owen A. Ung MBBS FRACS FAICD

Owen Ung is a breast and endocrine surgeon and Director of the Metro North Comprehensive Breast Cancer Institute. He is a committed clinician, educator and researcher.

Affiliations:
Professor of Surgery, University of Queensland
Visiting specialist – the Royal Brisbane and Women’s Hospital, Wesley Private and St Andrews War Memorial Hospital in Brisbane, Queensland, Australia.

Professional representations:
Federal Counciller for the Australian Medical Association (AMA) and the Royal Australasian College of Surgeons (RACS) – Director Medical Insurance Australia (MIGA) – President Elect and executive member of Breast Surgery International (BSI) of the international Surgical Society (ISS).

Owen has obtained extensive administrative and management experience through his various clinical leadership roles and is active on numerous State and National Committees.

Dr. Frank A. Vicini has held multiple academic appointments and has been involved in numerous clinical studies involving breast and prostate cancer. He has designed, developed and completed numerous phase I/II and III NIH/NCI clinical trials to evaluate new and improved techniques to treat patients with Stage I and II breast cancer. Dr. Vicini has authored over 300 peer-reviewed articles and presented his research at national and international meetings. He is a visiting professor in both the United States and Europe, authored multiple chapters in textbooks and is on the editorial board of several oncology journals. In addition, he is listed as one of the few oncologists in “Best Oncology Doctors in America.” Dr. Vicini was recently named 21st Century Oncology’s National Principal Investigator.

Melanie Walker is a specialist breast surgeon in private and public practice in Melbourne.
She is the current President of BreastSurgANZ, a founding member of the Society and has held various roles on Council and the Executive Council since the Society’s inception.

After graduating from Monash University in 1996 and training in general surgery at the Alfred Hospital, she undertook a further three years of training in breast surgery in the UK, including an Oncoplastic Fellowship year at the Canniesburn Plastic Surgery Unit, Glasgow, where she developed her special interest in oncoplastic breast surgery and breast ultrasound. Melanie is committed to ensuring standards in the training and credentialing of breast surgeons.

Associate Professor Sanjay Warrier is a dedicated and compassionate Consultant Breast Oncology and Oncoplastic Surgeon at Chris O’Brien Lifehouse, Royal Prince Alfred and Mater Hospitals. He is also a Visiting Medical Officer at BreastScreen NSW.
He completed his undergraduate medical training at the University of New South Wales in 2002 with post fellowship training specialising in breast oncology and oncoplastic surgery within Prince of Wales and the Royal Prince Alfred Hospital networks.
In 2013, Sanjay’s work on Hedgehog signaling, in collaboration with Garvan Institute, won the Patron’s Prize at RPAH for best scientific oral presentation.
He is an Associate Professor at the University of Sydney with the Royal Prince Alfred Institute of Academic Surgery and is the lead researcher at the Institute with the goal to improve patient outcomes through the application of the latest research and innovative technology available both in Australia and around the world.
In 2017 Sanjay was the pioneer surgeon in Australia of the SPY Elite System in his theatres. This technology is the most advanced fluorescent imaging system in the world to accurately identify healthy blood flow around remaining tissue, assisting with the decisions for immediate breast reconstructive surgery following breast-gland removal.
A/Prof Warrier is the Course Co-Founder and Co-Coordinator of the Oncoplastic Masters Course at the University of Sydney.
Sanjay is a Board member of the Sydney Breast Cancer Foundation, a role that he is honoured to hold.
He is the current Chairman of Post-Fellowship Training for BreastSurgANZ, a role that involves training of future breast surgeons in Australia and New Zealand, and the current Site Director of Surgical Training at RPAH.
Sanjay is passionate about patient care, teaching, research and in the past year has presented at various national and international conferences.

Associate Professor Nicholas Wilcken MB BS, PhD, FRACP,
Nicholas Wilcken is Director of Medical Oncology at the Crown Princess Mary Cancer Centre Westmead, Senior Staff Specialist at Nepean Hospital, and Associate Professor of Medicine, University of Sydney, Australia.
Medical oncology training was at Royal Prince Alfred Hospital, Sydney, followed by a PhD in breast cancer cell cycle control at the Garvan Institute, Sydney.
His clinical interests are in breast cancer and colo-rectal cancer. Research interests include translational oncology, systematic reviews and breast cancer clinical trials.
He is currently the Co-ordinating Editor of the Cochrane Collaboration’s Breast Cancer Group and Chair of the ANZ Breast Cancer Trials Group, Scientific Advisory Committee. He has been an invited expert panel member for the last two St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.

Dr Belinda Yeo(FRACP, MD, MBBS, BA)
Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays. She is co-lead of the VCCC Research and Education Stream for Breast Cancer, she is a clinical trial investigator and continues her translational research investigating improving personalization and minimising toxicities for patients with breast cancer.

Milita Zaheed is a staff specialist in Cancer Genetics at Prince of Wales Hospital and is also the medical lead for ACT Cancer Genetics service. She is a Medical Oncologist and trained in Cancer Genetics through Royal Australian College of Physicians with an NSW Cancer Institute two-year fellowship grant. She is currently doing a PhD in cancer genetics through Garvan Institute investigating opportunities to improve identification of cancer predisposition syndromes in the genomic era of cancer care. She is a past National Medical Oncology trainee representative, current executive committee member of Young Oncologist Group of Australia and COSA Global Oncology Interest Group.

Dr. Nick Zdenkowski is a medical oncologist with a predominant breast cancer focus in his multidisciplinary clinical practices at Lake Macquarie and Maitland Private Hospitals in NSW Australia. He is a conjoint senior lecturer with the University of Newcastle and works as a medical advisor to Breast Cancer Trials, Australia’s collaborative breast cancer research group, across their trials program. His research interest is in neoadjuvant systemic therapy for breast cancer, and in shared decision-making for cancer patients. His PhD thesis led to the development of a decision aid for the neoadjuvant population.